Tesamorelin/Ipamorelin (Blend) – 5 mg / 5 mg

Tesamorelin / Ipamorelin Blend combines the properties of
Tesamorelin, a synthetic analog of growth hormone–releasing hormone (GHRH),
with Ipamorelin, a selective growth hormone secretagogue (ghrelin receptor agonist).
This synergistic blend is researched for its ability to enhance natural growth hormone release,
stimulate IGF-1 production, support lean muscle growth, reduce visceral fat,
and accelerate recovery processes. The dual mechanism offers a more comprehensive approach
compared to using either peptide alone.

1. Growth Hormone & IGF-1 Secretion

Tesamorelin stimulates the pituitary via GHRH receptors,
while Ipamorelin targets ghrelin receptors to induce pulsatile GH release.
Together, they provide a synergistic increase in GH and IGF-1 without excessive cortisol or prolactin stimulation.

2. Body Composition & Fat Reduction

Tesamorelin has been FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy,
while Ipamorelin research links it to fat metabolism and lean muscle preservation.
The blend may therefore support improved body composition outcomes in research models.

3. Muscle Growth & Recovery

Both peptides support protein synthesis, tissue regeneration, and recovery from injury.
The combination has been studied in contexts of muscle wasting, injury repair, and performance recovery.

4. Anti-Aging & Regenerative Potential

With GH decline associated with aging, the blend is being investigated for healthy longevity,
improved energy, better sleep, and regenerative support.

Future research will likely evaluate the long-term safety of combined GHRH analogs and secretagogues,
their role in age-related decline, and therapeutic potential in metabolic syndrome,
muscle wasting disorders, and regenerative medicine.
Studies may also assess optimized dosing protocols to maximize synergy while minimizing risks.